ReviewTranslational lung cancer research2021
Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review.
Review in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- All-LCP Terahertz Metasensor with Dual Quasi-BIC Resonances for Dual-Range Refractive Index Sensing.Biosensors · 2026Article
- Knowledge, attitudes and practices among rosacea patients in Chongqing, China: a cross-sectional study.BMJ open · 2025Article
- 'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.Journal of cancer research and clinical oncology · 2024Article
- Article
- Can spectral computed tomography (CT) replace perfusion CT to assess the histological classification of non-small cell lung cancer?Quantitative imaging in medicine and surgery · 2023Article
- NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know.Diagnostics (Basel, Switzerland) · 2023Review
- Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Medical sciences (Basel, Switzerland) · 2023Review
- Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.EXCLI journal · 2023Review
- The integrated comprehension of lncRNA HOXA-AS3 implication on human diseases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Genome-wide analysis of Chinese keloid patients identifies novel causative genes.Annals of translational medicine · 2022Article
- Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer ranks first as the cause of cancer-associated deaths gobally. The American Cancer Society estimates for 228,820 new cases and 135,720 deaths from lung cancer in the United States for the year 2020. Targeted treatment options have rapidly emerged for non-small cell lung cancer (NSCLC) within the past decade. Screening for molecular aberrations is mainly done by tissue biopsy. However, in some cases a biopsy is not possible, or patients do not consent to it. Hence, liquid biopsy remains the only option. Relevant data about the topic of liquid biopsy, with a special focus on NSCLC, was obtained via a PubMed search. We included mainly literature published from 2010 onwards, omitting older studies whenever possible. With this review of the literature, we give an overview of different liquid biopsy approaches, as well as their respective advantages and disadvantages. We have reviewed the assessment of epidermal growth factor receptor (EGFR) mutation status in particular, and go into detail with current use of liquid biopsy in everyday clinical practice. Today, liquid biopsy is still infrequently used, depending on the treatment center, but popularity is steadily increasing. Various different approaches are already available, but costs and level of sensitivity significantly differ between techniques. By using liquid biopsy more widely in selected patients, complication rates can be reduced, and constant disease monitoring is made considerably easier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.